Market Overview

Isis Pharma Issues Update on CHMP Opinion on KYNAMRO

Related ISIS
Defense Stock Roundup: Textron Reports Impressive Q2 Earnings, Lockheed Wins Indian Super Hercules Contract
Isis Pharmaceuticals Initiates Phase 2 Study Of ISIS-APO(a) Rx In Patients With High Lp(a)

Isis Pharmaceuticals Inc. (NASDAQ: ISIS) today announced that following Genzyme's request for re-examination, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) confirmed its previous position and has maintained a negative opinion regarding the marketing authorization application (MAA) for KYNAMRO^TM (mipomersen) as a treatment for patients with Homozygous Familial Hypercholesterolaemia (HoFH).

The FDA approved KYNAMRO in the United States in January 2013 for the treatment of patients with Homozygous Familial Hypercholesterolaemia.

Posted-In: News

 

Most Popular

Related Articles (ISIS)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free